Two Men Fined For Selling Erectile Dysfunction Drugs, UK
The Medicines and Healthcare products Regulatory Agency successfully prosecuted two men on 7 February 2008 at Bradford Magistrates Court for selling unlicensed medicines. David Tetley, (61) retired, and Stephen Evans, (49) unemployed, of 554 Leeds Road, Idle, Bradford, BD10 8JH, they pleaded guilty to the illegal sale and supply of Kamagra, Kamagra Oral Jelly and Loveagra.
Daily Vardenafil For 6 Months Has No Detrimental Effects On Semen Characteristics Or Reproductive Hormones In Men With Normal Baseline Levels
UroToday.com - This a randomized, double-blind, placebo controlled, parallel group, multicenter study involving 200 men with or without erectile dysfunction. Men (25-64 years of age) did not have ejaculatory dysfunction. Subjects were randomized to daily treatment with vardenafil, sildenafil or placebo for 6 months.
High Levels Of The Molecule Adenosine Linked To Priapism
Priapism (prolonged penile erection in the absence of sexual interest) is common in male individuals with sickle cell disease (SCD), a blood disorder characterized by abnormally shaped red blood cells. Priapism is considered a medical emergency because it is associated with decreased blood flow to the erectile tissue, which can result in erectile tissue damage and, subsequently, erectile dysfunction and impotence.
Erection Hardness Scale Proves Effective In Assessing Erection Quality
The Erection Hardness Scale (EHS), an easy-to-use, four-point scale for erectile dysfunction (ED), provides a reliable measure of erection hardness and an indicator of other health and wellbeing outcomes, according to new data reported at the European Association of Urology.
Erectile Dysfunction Not Only Interferes With Romance, It Warns Of Future Heart Disease
Erectile dysfunction is always a matter of the heart, but new research shows that more than romance is at stake. Two new studies of men with type 2 diabetes found that erectile dysfunction (ED) was a powerful early warning sign for serious heart disease, including heart attack and death.
Levitra reg; Therapy Suitable For Men With High Cholesterol
At the 23rd Annual European Association of Urology (EAU) Congress, results were presented which added evidence that Levitra (vardenafil HCI) works very well in men with dyslipidemia.(1) The double-blind, placebo-controlled trial in about 400 men showed that Levitra significantly improved the ability of men with erectile dysfunction (ED) and high cholesterol, to achieve and maintain an erection for successful sexual intercourse.
Definition Of Premature Ejaculation By International Society For Sexual Medicine ISSM
Despite the fact that it has long been a major concern for men, an evidence-based definition for premature ejaculation has not existed until now. In October 2007, the International Society for Sexual Medicine (ISSM) gathered the world's leading sexual health experts to develop an evidence-based definition of premature ejaculation.
Maxi-K Gene Transfer May Prove To Be Safe And Effective Erectile Dysfunction Treatment
Maxi-K gene therapy may be a safe and effective future option for men whose erectile dysfunction (ED) is not treatable with oral therapy. Two studies presented at the 103rd Annual Scientific Meeting of the American Urological Association (AUA) may give hope to these individuals.
FDA Requests Recall Of Xiadafil VIP Tabs
The U.S. Food and Drug Administration requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person's blood pressure and can cause other life-threatening side effects.
Rexahn Pharmaceuticals Initiates Phase II Trial For ZoraxelTM To Treat Erectile Dysfunction
Rexahn Pharmaceuticals, Inc. (AMEX:RNN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, announced that the Company has initiated a Phase II clinical trial for its lead clinical compound ZoraxelTM, for the treatment of Erectile Dysfunction (ED).